1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
United Therapeutics Corporation

United Therapeutics Corporation

UTHR
United Therapeutics CorporationUS flagNASDAQ Global Select
535.83
USD
+6.49
- -
22.74BMarket Cap

Total Valuation

United Therapeutics Corporation carries a market capitalization of 22.74B, placing it among publicly traded companies globally. Its enterprise value stands at 23.89B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap22.74B
Enterprise Value23.89B

Share Statistics

United Therapeutics Corporation currently has 42.16M shares outstanding.

Shares Outstanding42.16M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

United Therapeutics Corporation trades at a trailing price-to-earnings ratio of 20.23. The price-to-sales ratio is 8.22, and the price-to-book ratio stands at 2.95.

PE Ratio20.23
PS Ratio8.22
PB Ratio2.95
P/TBV Ratio4.50
P/FCF Ratio13.36
P/OCF Ratio16.66

Enterprise Valuation

On an enterprise value basis, United Therapeutics Corporation trades at an EV/EBITDA multiple of 15.44 and an EV/FCF ratio of 11.26. The EV/Sales ratio of 7.54 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.38 provides insight into valuation relative to core operating earnings.

EV / Sales7.54
EV / EBITDA15.44
EV / EBIT16.38
EV / FCF11.26

Financial Position

United Therapeutics Corporation maintains a current ratio of 4.79, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

Current Ratio4.79
Quick Ratio4.12
Debt / EquityN/A
Debt / EBITDAN/A
Interest Coverage94.34

Financial Efficiency

United Therapeutics Corporation posts a return on equity of 15.72 and a return on invested capital of 18.09.

Return on Equity (ROE)15.72
Return on Assets (ROA)17.81
Return on Invested Capital (ROIC)18.09
Return on Capital Employed (ROCE)15.69
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover2.47

Taxes

Over the trailing twelve months, United Therapeutics Corporation has paid 321.30M in income taxes, reflecting an effective tax rate of 19.97.

Income Tax321.30M
Effective Tax Rate19.97

Stock Price Statistics

United Therapeutics Corporation's stock has gained approximately 82.80227% over the past 52 weeks. The 50-day moving average sits at 552.44, while the 200-day moving average is 510.79.

Beta (5Y)N/A
52-Week Price Change82.80227%
50-Day Moving Average552.44
200-Day Moving Average510.79
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, United Therapeutics Corporation generated 3.17B in revenue and converted that into 1.29B in net income, yielding earnings per share of 27.09. EBITDA reached 1.55B, while operating income came in at 1.46B.

Revenue3.17B
Gross Profit2.74B
Operating Income1.46B
Pretax Income1.61B
Net Income1.29B
EBITDA1.55B
EBIT1.46B
Earnings Per Share (EPS)27.09

Balance Sheet

Total book value stands at 8.83B, with working capital of 2.27B providing operational flexibility.

Cash & Cash Equivalents2.15B
Total DebtN/A
Net Debt-1.28B
Equity (Book Value)8.83B
Book Value Per Share201.08
Working Capital2.27B

Cash Flow

United Therapeutics Corporation produced 1.56B in operating cash flow over the past twelve months. After subtracting -546.40M in capital expenditures, free cash flow totaled 1.02B - equivalent to 23.15 per share.

Operating Cash Flow1.56B
Capital Expenditures-546.40M
Free Cash Flow1.02B
FCF Per Share23.15

Margins

United Therapeutics Corporation operates with a gross margin of 86.58, reflecting its pricing power and cost economics. The operating margin of 46.02 and net profit margin of 40.61 provide insight into operational efficiency.

Gross Margin86.58
Operating Margin46.02
Pretax Margin50.75
Profit Margin40.61
EBITDA Margin48.81

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield9.75
FCF Yield7.49

Stock Splits

United Therapeutics Corporation's most recent stock split took place on September 23, 2009 with a 1:2 split ratio.

Last Split Date9/23/2009
Split Ratio1:2

Scores

United Therapeutics Corporation posts an Altman Z-Score of 22.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score22.72